Bellicum Pharmaceuticals Bilan de santé
Santé financière contrôle des critères 4/6
Bellicum Pharmaceuticals has a total shareholder equity of $4.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.9M and $2.2M respectively.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$5.91m |
| Fonds propres | US$4.60m |
| Total du passif | US$2.25m |
| Total des actifs | US$6.85m |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: BLCM's short term assets ($6.8M) exceed its short term liabilities ($2.2M).
Passif à long terme: BLCM has no long term liabilities.
Historique et analyse du ratio d'endettement
Niveau d'endettement: BLCM is debt free.
Réduire la dette: BLCM has no debt compared to 5 years ago when its debt to equity ratio was 38.5%.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: BLCM has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: BLCM has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.6% each year.